<p>The fraction of antibodies remaining bound after competition with 30 µg of the indicated competitor are depicted on the y-axis, boxes indicate median and quartile ranges. P-DI-II-III = FVO AMA1 ectodomain amino acids 25–545, DI-II = FVO-AMA1 amino acids 97–442, DII-III = FVO AMA1 amino acids 303–545 and DII = FVO AMA1 amino acids 303–442. Treatment groups are indicated by Adjuvant name and AMA1 dose, respectively.</p
<p>Binding of biotinylated CR3014 (A) and CR3022 (B) was analyzed in the presence of competitor CR30...
<p>Titration series of sera from two weeks after the third protein boost were competed with biotinyl...
<p>(A) Schematic representation of peptides used for scanning the binding sites of anti-MPER. (B) Re...
<p>Concentration of competitor antigen is depicted on the x-axis (µg mL<sup>−1</sup>) and the fracti...
<p>Antibody avidity is expressed as the amount of NaSCN required to dissociate 50% of bound antibodi...
<p>The box plots (see Statistical Analysis section for description) represent anti-CSP titers and an...
a<p>Competing MAbs, SFTS patients derived were designated as “H” for the first letter; and mouse der...
<p>Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).</p><p>7A...
<p>Treatment groups are indicated by Adjuvant name and AMA1 dose, respectively.</p
<p>Microtiter plates were coated with pandemic H1N1 A/California/04/2009 rHA (125 ng/well) and subse...
<p>Results were expressed as percent binding of HRP-conjugated mAbs. The amount of binding obtained ...
<p>Competition ELISA to determine the capacity of peptides to block binding of anti-ApoA-I antibodie...
<p>(<b>A</b>) Groups 1A and 2A and (<b>B</b>) groups 1B and 2B total IgG ELISA responses against 3D7...
<p>Increasing concentrations of GST-BAP31 were pre-incubated with 297-D4 and 144-A8 in the solution ...
<p><sup></sup> GIA values are mean of 3 or more experiments against 3D7 strain.</p><p><sup>#</sup> 1...
<p>Binding of biotinylated CR3014 (A) and CR3022 (B) was analyzed in the presence of competitor CR30...
<p>Titration series of sera from two weeks after the third protein boost were competed with biotinyl...
<p>(A) Schematic representation of peptides used for scanning the binding sites of anti-MPER. (B) Re...
<p>Concentration of competitor antigen is depicted on the x-axis (µg mL<sup>−1</sup>) and the fracti...
<p>Antibody avidity is expressed as the amount of NaSCN required to dissociate 50% of bound antibodi...
<p>The box plots (see Statistical Analysis section for description) represent anti-CSP titers and an...
a<p>Competing MAbs, SFTS patients derived were designated as “H” for the first letter; and mouse der...
<p>Antibody depletion after competition ELISA, values reported as mean % depletion (95%CI).</p><p>7A...
<p>Treatment groups are indicated by Adjuvant name and AMA1 dose, respectively.</p
<p>Microtiter plates were coated with pandemic H1N1 A/California/04/2009 rHA (125 ng/well) and subse...
<p>Results were expressed as percent binding of HRP-conjugated mAbs. The amount of binding obtained ...
<p>Competition ELISA to determine the capacity of peptides to block binding of anti-ApoA-I antibodie...
<p>(<b>A</b>) Groups 1A and 2A and (<b>B</b>) groups 1B and 2B total IgG ELISA responses against 3D7...
<p>Increasing concentrations of GST-BAP31 were pre-incubated with 297-D4 and 144-A8 in the solution ...
<p><sup></sup> GIA values are mean of 3 or more experiments against 3D7 strain.</p><p><sup>#</sup> 1...
<p>Binding of biotinylated CR3014 (A) and CR3022 (B) was analyzed in the presence of competitor CR30...
<p>Titration series of sera from two weeks after the third protein boost were competed with biotinyl...
<p>(A) Schematic representation of peptides used for scanning the binding sites of anti-MPER. (B) Re...